hydroxyurea and Pulmonary Hypertension studies

Research Excerpts

Excerpt	Relevance	Reference
" Pregnancy is a high-risk situation for the mother and child The efficacy and safety of hydroxyurea and long-term blood transfusions in adults with sickle cell disease are currently under investigation."	4.84	[New issues in adult sickle sell disease]. ( Girot, R; Lionnet, F; Stankovic, K, 2008)
" Improved understanding of the natural history of complications such as stroke and pulmonary hypertension, effects of treatments, such as hydroxyurea and blood transfusions, as well as the impact of transplantation on organ damage are likely to influence the timing and indication of transplantation."	4.84	Hematopoietic cell transplantation: a curative option for sickle cell disease. ( Krishnamurti, L, 2007)
" Whereas the orally administrable iron-chelating agent deferasirox is likely to increasingly take the place of desferioxamine (which can only be given parenterally), effective treatment of priapism in SCD remains a distressing challenge."	4.83	Investigational agents for sickle cell disease. ( Okpala, I, 2006)
"A 65-year-old man was diagnosed with polycythemia vera (PV) and treated with hydroxyurea."	3.85	Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. ( Matsumura, A; Miyazaki, T; Nakajima, H; Nakajima, Y; Nakayama, N; Tachibana, T; Takahashi, H, 2017)
"SCD patients, in steady state and asymptomatic for pulmonary hypertension, were studied stressing on hydroxyurea therapy, serum ferritin, urinary albumin creatinine ratio (UACR), high-sensitivity C-reactive protein (hs-CRP) and sFas/sFasL levels."	3.83	Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease. ( Adly, AA; Andrawes, NG; Eladawy, R; Ismail, EA; Mahmoud, MM, 2016)
" It appears to be a complication of chronic hemolysis, is resistant to hydroxyurea therapy, and confers a high risk of death."	3.72	Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. ( Blackwelder, WC; Brown, B; Castro, O; Coles, WA; Ernst, I; Gladwin, MT; Hunter, LA; Jison, ML; Minter, K; Nichols, JS; Ognibene, FP; Plehn, JF; Rodgers, GP; Sachdev, V; Schechter, AN; Shizukuda, Y, 2004)
"Sickle cell disease is a genetic haemoglobin disorder, which can cause severe pain, significant end-organ damage, pulmonary complications, and premature death."	2.53	Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. ( Cho, G; Estcourt, LJ; Fortin, PM; Hambleton, IR; Hopewell, S; Trivella, M, 2016)
" Accordingly, we conclude that clinical trials in SCD designed to increase the bioavailability of NO or association studies in which SCD clinical manifestations are related to plasma hemoglobin via its surrogates should be viewed with caution."	2.46	Pulmonary hypertension and nitric oxide depletion in sickle cell disease. ( Bunn, HF; Dover, GJ; Hebbel, RP; Nathan, DG; Platt, OS; Rosse, WF; Ware, RE, 2010)
"Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen."	2.41	[What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000)
"Hydroxyurea-treated patients had higher apelin levels than untreated ones (P=0."	1.43	Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease. ( Elbarbary, NS; Fahmy, E; Ismail, EA; Roushdy, A, 2016)
"In treated hydroxyurea group, 11."	1.37	Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study. ( Amoozgar, H; Cheriki, S; Farhani, N; Karimi, M; Khodadadi, N, 2011)
"In adults, pulmonary hypertension is significantly associated with mortality."	1.35	Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. ( Bazzy-Asaad, A; Carbonella, J; Friedman, A; Pashankar, FD, 2009)
"Pulmonary hypertension is common among Nigerian SCD patients."	1.35	Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. ( Akpanpe, P; Aliyu, N; Aliyu, ZY; Attah, E; Babadoko, A; Gladwin, MT; Gordeuk, V; Kato, GJ; Mamman, AI; Mendelsohn, L; Sachdev, V; Suleiman, Y; Yusuf, J, 2008)
"The EMH-related pleural effusion is rarely referred to in the literature of thalassemia."	1.33	Extramedullary hematopoiesis-related pleural effusion: the case of beta-thalassemia. ( Aessopos, A; Farmakis, D; Kati, M; Moyssakis, I; Polonifi, K; Tassiopoulos, S; Tsironi, M, 2006)
"Pulmonary hypertension was associated with an increased risk of death (relative risk, 9."	1.33	Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. ( Ataga, KI; Hinderliter, A; Jones, S; Moore, CG; Olajide, O; Orringer, EP; Strayhorn, D, 2006)
"Despite treatment for pulmonary hypertension and provision of respiratory support, the patient died."	1.33	Pulmonary hypertension in a child with juvenile myelomonocytic leukemia secondary to pulmonary leukemic cell infiltration. ( Alioglu, B; Demirhan, B; Erbay, A; Ozbek, N; Ozyurek, E; Varan, B, 2006)

Research

Studies (40)

Authors

Clinical Trials (18)

Trial Overview

Trial Outcomes

Assess Change of Borg Dyspnea Index

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (5.00)	18.7374
1990's	1 (2.50)	18.2507
2000's	17 (42.50)	29.6817
2010's	18 (45.00)	24.3611
2020's	2 (5.00)	2.80

Authors	Studies
Chan, KH	1
Rizvi, SH	1
De Jesus-Rojas, W	1
Stark, JM	1
Mosquera, RA	1
Prada-Ruiz, AC	1
Gonzales, T	1
Brown, DL	1
Menon, NM	1
Nguyen, TT	1
Jon, CK	1
Yadav, A	1
Al Kahf, S	1
Roche, A	1
Baron, A	1
Chantalat-Auger, C	1
Savale, L	2
Tachibana, T	1
Nakayama, N	1
Matsumura, A	1
Nakajima, Y	1
Takahashi, H	1
Miyazaki, T	1
Nakajima, H	1
Desai, PC	1
May, RC	1
Jones, SK	1
Strayhorn, D	2
Caughey, M	1
Hinderliter, A	2
Ataga, KI	3
Klings, ES	2
Machado, RF	2
Barst, RJ	1
Morris, CR	1
Mubarak, KK	1
Gordeuk, VR	1
Kato, GJ	3
Gibbs, JS	1
Castro, O	2
Rosenzweig, EB	1
Sood, N	1
Hsu, L	1
Wilson, KC	2
Telen, MJ	1
Decastro, LM	1
Krishnamurti, L	2
Steinberg, MH	2
Badesch, DB	1
Gladwin, MT	7
Furlow, B	1
Hayes, MM	1
Vedamurthy, A	1
George, G	1
Dweik, R	1
Thomson, CC	1
Adly, AA	2
Ismail, EA	3
Andrawes, NG	1
Mahmoud, MM	1
Eladawy, R	1
Elbarbary, NS	1
Roushdy, A	1
Fahmy, E	1
Estcourt, LJ	1
Fortin, PM	1
Hopewell, S	1
Trivella, M	1
Hambleton, IR	1
Cho, G	1
Pashankar, FD	1
Carbonella, J	1
Bazzy-Asaad, A	1
Friedman, A	1
Karimi, M	2
Borzouee, M	1
Mehrabani, A	1
Cohan, N	1
Girot, R	1
Stankovic, K	1
Lionnet, F	1
Dahoui, HA	1
Hayek, MN	1
Nietert, PJ	1
Arabi, MT	1
Muwakkit, SA	1
Saab, RH	1
Bissar, AN	1
Jumaa, NM	1
Farhat, FS	1
Dabbous, IA	1
Bitar, FF	1
Abboud, MR	1
Bunn, HF	1
Nathan, DG	1
Dover, GJ	1
Hebbel, RP	1
Platt, OS	1
Rosse, WF	1
Ware, RE	1
Rees, DC	1
Williams, TN	1
Amoozgar, H	1
Farhani, N	1
Khodadadi, N	1
Cheriki, S	1
Mokhtar, GM	1
Tantawy, AA	1
Connes, P	1
Machado, R	1
Hue, O	1
Reid, H	1
Bartolucci, P	1
Galactéros, F	1
Montani, D	1
Bergot, E	1
Günther, S	1
Bergeron, A	1
Bourdin, A	1
Bouvaist, H	1
Canuet, M	1
Pison, C	1
Macro, M	1
Poubeau, P	1
Girerd, B	1
Natali, D	1
Guignabert, C	1
Perros, F	1
O'Callaghan, DS	1
Jaïs, X	1
Tubert-Bitter, P	1
Zalcman, G	1
Sitbon, O	1
Simonneau, G	1
Humbert, M	1
Ballas, SK	1
Kesen, MR	1
Goldberg, MF	1
Lutty, GA	1
Dampier, C	1
Osunkwo, I	1
Wang, WC	1
Hoppe, C	1
Hagar, W	1
Darbari, DS	1
Malik, P	1
Al-Zahrani, H	1
Gupta, V	1
Minden, MD	1
Messner, HA	1
Lipton, JH	1
Sachdev, V	2
Jison, ML	1
Shizukuda, Y	1
Plehn, JF	1
Minter, K	1
Brown, B	1
Coles, WA	2
Nichols, JS	2
Ernst, I	1
Hunter, LA	2
Blackwelder, WC	2
Schechter, AN	1
Rodgers, GP	1
Ognibene, FP	1
Martyr, S	1
Brennan, ML	1
Hazen, SL	1
Okpala, IE	1
Aessopos, A	1
Tassiopoulos, S	1
Farmakis, D	1
Moyssakis, I	1
Kati, M	1
Polonifi, K	1
Tsironi, M	1
Moore, CG	1
Jones, S	1
Olajide, O	1
Orringer, EP	1
Okpala, I	1
Alioglu, B	1
Demirhan, B	1
Ozyurek, E	1
Varan, B	1
Erbay, A	1
Ozbek, N	1
Lode, HN	1
Krings, G	1
Schulze-Neick, I	1
Dähmlow, S	1
Schroeder, U	1
Bonnet, R	1
DaPalma, J	1
Luck, W	1
Strauss, G	1
Berger, F	1
Gaedicke, G	1
Voskaridou, E	1
Tsetsos, G	1
Tsoutsias, A	1
Spyropoulou, E	1
Christoulas, D	1
Terpos, E	1
Aliyu, ZY	1
Gordeuk, V	1
Babadoko, A	1
Mamman, AI	1
Akpanpe, P	1
Attah, E	1
Suleiman, Y	1
Aliyu, N	1
Yusuf, J	1
Mendelsohn, L	1
Hinson, JM	1
Hutchison, AA	1
Ogletree, ML	1
Brigham, KL	2
Snapper, JR	1
Hachulla, E	1
Rose, C	1
Trillot, N	1
Caulier-Leleu, MT	1
Pasturel-Michon, U	1
Perkett, EA	1
Meyrick, B	1
Engelhardt, B	1
Sandberg, K	1
Bratton, D	1
Van den Abbeele, A	1
Grogaard, J	1
Hellerqvist, C	1
Sundell, H	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease[NCT02651272]	Phase 2	4 participants (Actual)	Interventional	2015-07-31	Terminated (stopped due to Unable to enroll IRB approved sample of participants.)
A Substudy of the CADRE Study: Determination of Clinical Markers in Patients With Extreme Sickle Cell Disease Phenotype[NCT03352986]		300 participants (Anticipated)	Observational	2017-05-15	Recruiting
Aerobic Physical Fitness and Health-related Quality of Life in Children With Sickle Cell Disease.[NCT05995743]		72 participants (Actual)	Observational	2021-11-01	Completed
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082]		64 participants (Actual)	Interventional	2015-09-30	Completed
Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living With Sickle- Cell Disease in France[NCT04413539]		1,088 participants (Actual)	Observational	2020-06-02	Completed
Treatment With Hydoxycarbamide and L-Carnitine in Adult Patients With Severe Forms of Sickle Cell Anemia: An Overview[NCT05081349]	Phase 4	91 participants (Actual)	Interventional	2017-01-10	Completed
Evaluation of Sickle Cell Liver Disease[NCT01950429]		42 participants (Actual)	Observational	2013-10-16	Completed
Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial[NCT05253781]	Phase 3	476 participants (Anticipated)	Interventional	2020-07-01	Recruiting
National Transfusion Treatment Survey in Patients With Sickle Cell Disease (SCD)[NCT03397017]		200 participants (Actual)	Observational	2016-07-01	Completed
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease: a Feasibility Trial[NCT02960503]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2016-09-30	Withdrawn (stopped due to Key personnel moved to new location. Therefore, we had insufficient resources to initiate the trial.)
Long-Term, Open-Label, Multicenter, Extension Study of Bosentan in Patients With Pulmonary Hypertension Associated With Sickle Cell Disease Completing a Double-Blind ASSET Study (AC-052-368 or AC 052-369)[NCT00360087]	Phase 3	236 participants	Interventional	2006-03-31	Terminated (stopped due to Slow enrollment)
Role of Nitric Oxide Scavenging by Plasma Hemoglobin and Identification of Hemolysis-Associated Pulmonary Hypertension in Malaria[NCT00527163]		103 participants (Actual)	Observational	2007-09-04	Completed
Serum Brain Natriuretic Peptide Levels and Its Correlation With Echocardiographic Measurements Suggestive of Pulmonary Hypertension in Pediatric Patients With Sickle Cell Disease[NCT01023451]		21 participants (Actual)	Observational	2009-12-31	Completed
Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901]		150 participants (Actual)	Observational	2009-12-31	Completed
Erythrocyte Glutamine Level Relation to Pulmonary Hypertension Risk in Beta Thalassemia Major Children in Assiut University Children Hospital[NCT03133169]		80 participants (Actual)	Observational	2017-06-01	Completed
Heart, Arteries and Sikle Cell Disease, a Multicentric Cohort of Cardiovascular Complications in Subsaharan Africa[NCT03114137]		4,500 participants (Anticipated)	Observational [Patient Registry]	2012-03-31	Recruiting
An Evaluation of Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Patients With Sickle Cell Anemia: A Retrospective Data Review[NCT01783093]		209 participants (Actual)	Observational	2009-12-31	Completed
Exploratory Studies of Psychophysical Pain Phenotyping and Genetic Variability in Sickle Cell Disease[NCT01441141]		67 participants (Actual)	Observational	2012-06-17	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Borg Dyspnea Index (BDI) is a 0 to 10 rated self reported numerical score used to measure dyspnea during submaximal exercise and will be administered immediately following the 6MWT. The higher the score, the more dyspnea. (NCT02651272)
Timeframe: Baseline, 16 weeks

Change in 6 Minute Walk Distance (6MWD)

Intervention	score on a scale (Number)
Macitentan	6

The 6 minute walk test (6MWT) assesses distance walked over 6 minutes (6MWD) as a sub-maximal test of aerobic capacity/endurance. Participants will walk at their normal pace for 6 minutes. (NCT02651272)
Timeframe: Baseline, 16 weeks

Change in Cardiac Index (CI)

Intervention	meters (Number)
Macitentan	-89

Cardiac index (CI) will be measured in L/min/m^2. The normal range for CI is 2.5 to 4 L/min/m^2. (NCT02651272)
Timeframe: Baseline to Week 16

Change in Cardiac Output (CO)

Intervention	L/min/m^2 (Number)
Macitentan	.23

Cardiac output (CO) will be measured in L/min/m^2. The normal range for CO is 4 to 8 L/min/m^2. (NCT02651272)
Timeframe: Baseline, Week 16

Change in Diastolic Pulmonary Artery Pressure (PADP)

Intervention	L/min/m^2 (Number)
Macitentan	.29

PADP will be assessed by right heart catheterization. Normal range is 8-15 mmHg. (NCT02651272)
Timeframe: Baseline, 16 weeks

Change in NT-proB-type Natriuretic Peptide (NT-pro-BNP)

Intervention	mmHg (Number)
Macitentan	-5

The normal range for NT-pro-BNP is less than 300 picograms of BNP per milliliter (pg/ml) of blood; higher levels are less favorable. (NCT02651272)
Timeframe: Baseline, 16 weeks

Change in Right Arterial Pressure (RAP)

Intervention	pg/mL (Number)
Macitentan	10528

RAP will be assessed by right heart catheterization. Normal range is 2-6 mmHg. (NCT02651272)
Timeframe: Baseline, 16 weeks

Change in Systemic Vascular Resistance Index (SVR)

Intervention	mmHg (Number)
Macitentan	-5

Systemic vascular resistance (SVR) will be assessed with this formula Systemic Vascular Resistance (SVR) = 80x(Mean Arterial Pressure - Mean Venous Pressure or CVP) / Cardiac Output. Normal range is 800 - 1200 dynes-sec/cm-5. (NCT02651272)
Timeframe: Baseline, Week 16

Change in Systolic Pulmonary Artery Pressure (SPAP)

Intervention	dynes-sec/cm-5. (Number)
Macitentan	-528

SPAP will be assessed by right heart catheterization. Normal range is 15-25 mm Hg. (NCT02651272)
Timeframe: Baseline, 16 weeks

Change in Systolic Right Ventricular Pressure (RVSP)

Intervention	mmHg (Number)
Macitentan	7

RVSP will be assessed by right heart catheterization. Normal range is 15-25 mmHg. (NCT02651272)
Timeframe: Baseline, 16 weeks

Number of Participants With Treatment-emergent Adverse Events

Intervention	mmHg (Number)
Macitentan	3

The occurrence of treatment emergent AEs includes having any of the following: vaso-occlusive crises requiring hospitalization; acute congestive heart failure; hypotension (defined as a mean arterial pressure less than 60mmHg); decrease in hemoglobin concentration by greater than 1 g/dL. (NCT02651272)
Timeframe: 20 weeks

World Health Organization (WHO) Functional Classification

Intervention	Participants (Count of Participants)
Macitentan	0

"The WHO functional classification will be assessed and documented with the WHO Class.~Class I Patients with pulmonary hypertension (PH) but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.~Class II Patients with PH resulting in a slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.~Class III Patients with PH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope.~Class IV Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.~The Class is inversely related to function." (NCT02651272)
Timeframe: 16 weeks

Intervention	participants (Number)
	Class 1	Class 2	Class 3	Class 4
Macitentan	0	0	1	0

Article	Year
Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. The Cochrane database of systematic reviews, 2016, May-20, Issue:5 Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Transfusion; Female; Hum	2016
[New issues in adult sickle sell disease]. Bulletin de l'Academie nationale de medecine, 2008, Volume: 192, Issue:7 Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Cardiomyopathies; Combined Modality Therapy; Female;	2008
Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood, 2010, Aug-05, Volume: 116, Issue:5 Topics: Adult; Anemia, Sickle Cell; Animals; Child; Clinical Trials as Topic; Disease Models, Animal; Echoca	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Sickle-cell disease. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S	2010
Exercise limitation, exercise testing and exercise recommendations in sickle cell anemia. Clinical hemorheology and microcirculation, 2011, Volume: 49, Issue:1-4 Topics: Adaptation, Physiological; Anemia, Sickle Cell; Arterial Occlusive Diseases; Bronchial Hyperreactivi	2011
Clinical management of adult sickle-cell disease. Current opinion in hematology, 2012, Volume: 19, Issue:3 Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Hypertension, Pulmonary; Kidney Disea	2012
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. TheScientificWorldJournal, 2012, Volume: 2012 Topics: Anemia, Sickle Cell; Blood Transfusion; Clinical Trials as Topic; Disease Management; Gastrointestin	2012
Vascular events associated with alpha interferon therapy. Leukemia & lymphoma, 2003, Volume: 44, Issue:3 Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Foot Ulcer; Gangrene; Hemolytic-Uremic Syndrome	2003
Predicting clinical severity in sickle cell anaemia. British journal of haematology, 2005, Volume: 129, Issue:4 Topics: alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; Female; Fetal Hemoglobin; Genetic Predi	2005
New therapies for sickle cell disease. Hematology/oncology clinics of North America, 2005, Volume: 19, Issue:5 Topics: Acetamides; Anemia, Sickle Cell; Calcium Channel Blockers; Cell Adhesion; Fatty Acids, Omega-3; Huma	2005
Investigational agents for sickle cell disease. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:8 Topics: Acetamides; Anemia, Sickle Cell; Animals; Antihypertensive Agents; Antisickling Agents; Benzaldehyde	2006
Hematopoietic cell transplantation: a curative option for sickle cell disease. Pediatric hematology and oncology, 2007, Volume: 24, Issue:8 Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Female; Hemato	2007
[What vascular events suggest a myeloproliferative disorder?]. Journal des maladies vasculaires, 2000, Volume: 25, Issue:5 Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi	2000

Article	Year
Pulmonary hypertension screening in children with sickle cell disease. Pediatric blood & cancer, 2023, Volume: 70, Issue:1 Topics: Adolescent; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Hypertension, Pulmonary; Peptide Fragme	2023
Pulmonary hypertension in sickle cell disease. Presse medicale (Paris, France : 1983), 2023, Volume: 52, Issue:4 Topics: Anemia, Sickle Cell; Echocardiography; Heart Diseases; Humans; Hydroxyurea; Hypertension, Pulmonary	2023
Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. Internal medicine (Tokyo, Japan), 2017, Sep-15, Volume: 56, Issue:18 Topics: Aged; Humans; Hydroxyurea; Hypertension, Pulmonary; Japan; Male; Nitriles; Polycythemia Vera; Pulmon	2017
Longitudinal study of echocardiography-derived tricuspid regurgitant jet velocity in sickle cell disease. British journal of haematology, 2013, Volume: 162, Issue:6 Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Echocardiography; Female; Humans; Hydroxyurea	2013
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. American journal of respiratory and critical care medicine, 2014, Mar-15, Volume: 189, Issue:6 Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Antihypertensive Agents; Antisickling Agents; Cardiac Ca	2014
Pulmonary hypertension of sickle cell disease: new guidelines. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:4 Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Hypertension, Pulmonary; Practice Gui	2014
Pulmonary hypertension in sickle cell disease. Annals of the American Thoracic Society, 2014, Volume: 11, Issue:9 Topics: Anemia, Sickle Cell; Anticoagulants; Antisickling Agents; Echocardiography, Doppler; Erythrocyte Tra	2014
Revisiting the hyperhemolysis paradigm. Blood, 2015, Aug-06, Volume: 126, Issue:6 Topics: Anemia, Sickle Cell; Animals; Blood Transfusion; Brachial Artery; Cyclic N-Oxides; Female; Free Radi	2015
Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease. Cytokine, 2016, Volume: 79 Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Antisickling Agents; Apoptosis; Biomarkers; C-Reactive	2016
Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease. Blood cells, molecules & diseases, 2016, Volume: 57 Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Apelin; Arterial Pressure; Bilirubin; Biomarke	2016
Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. British journal of haematology, 2009, Volume: 144, Issue:5 Topics: Adolescent; Adult; Antisickling Agents; Child; Echocardiography, Doppler; Female; Follow-Up Studies;	2009
Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. European journal of haematology, 2009, Volume: 82, Issue:3 Topics: Adolescent; beta-Thalassemia; Case-Control Studies; Echocardiography; Female; Humans; Hydroxyurea; H	2009
Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering. Pediatric blood & cancer, 2010, Volume: 54, Issue:3 Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Echocardiograp	2010
Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study. European journal of haematology, 2011, Volume: 87, Issue:1 Topics: Adolescent; Adult; Antimetabolites; beta-Thalassemia; Case-Control Studies; Child; Child, Preschool;	2011
Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy. Hemoglobin, 2011, Volume: 35, Issue:4 Topics: Absorptiometry, Photon; Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Chelation Therapy;	2011
Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 2012, May-01, Volume: 125, Issue:17 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides;	2012
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec	2004
Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British journal of haematology, 2005, Volume: 130, Issue:6 Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Biomarkers; Cell Adhesion Molecules; E-Selectin; Endot	2005
Extramedullary hematopoiesis-related pleural effusion: the case of beta-thalassemia. The Annals of thoracic surgery, 2006, Volume: 81, Issue:6 Topics: Adult; Atrial Fibrillation; beta-Thalassemia; Blood Transfusion; Chest Tubes; Combined Modality Ther	2006
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. British journal of haematology, 2006, Volume: 134, Issue:1 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Urea Nitrogen; Chi-Square Distribution; Echoc	2006
Pulmonary hypertension in a child with juvenile myelomonocytic leukemia secondary to pulmonary leukemic cell infiltration. Pediatric hematology and oncology, 2006, Volume: 23, Issue:8 Topics: Anti-Bacterial Agents; Child, Preschool; Combined Modality Therapy; Diagnostic Errors; Fatal Outcome	2006
Pulmonary hypertension in a case of Hb-Mainz hemolytic anemia. Journal of pediatric hematology/oncology, 2007, Volume: 29, Issue:3 Topics: Adult; Anemia, Hemolytic; Blood Transfusion; Chronic Disease; Follow-Up Studies; Hemoglobins, Abnorm	2007
Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica, 2007, Volume: 92, Issue:6 Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Case-Control Studies; Female; Ferritins; Humans; Hydro	2007
Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. American journal of hematology, 2008, Volume: 83, Issue:6 Topics: Adolescent; Adult; Anemia, Sickle Cell; Case-Control Studies; Female; Humans; Hydroxyurea; Hypertens	2008
Effect of granulocyte depletion on altered lung mechanics after endotoxemia in sheep. Journal of applied physiology: respiratory, environmental and exercise physiology, 1983, Volume: 55, Issue:1 Pt 1 Topics: Agranulocytosis; Airway Resistance; Animals; Arachidonic Acid; Arachidonic Acids; Endotoxins; Escher	1983
Granulocyte depletion attenuates sustained pulmonary hypertension and increased pulmonary vasoreactivity caused by continuous air embolization in sheep. The American review of respiratory disease, 1990, Volume: 141, Issue:2 Topics: Animals; Chronic Disease; Embolism, Air; Granulocytes; Hydroxyurea; Hypertension, Pulmonary; Lung; L	1990
The role of granulocytes in the pulmonary response to group B streptococcal toxin in young lambs. Pediatric research, 1987, Volume: 21, Issue:2 Topics: Animals; Capillary Permeability; Granulocytes; Hydroxyurea; Hypertension, Pulmonary; Leukopenia; Lun	1987

hydroxyurea and Pulmonary Hypertension